MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Mink Therapeutics' second quarter 2025 conference call and webcast. All participants will be in a listen-only mode until the question and answer session. Please note that this event is being recorded. If anyone has any objections, you may disconnect at this time. I would now like to turn the conference over to Zach Arman from Mink's Investor Relations. Zach, please go ahead. Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data release, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, and Christine Klaskin, Principal Financial and Accounting Officer. Now, I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Thank you, Zach, and thank you all for joining us today. At Mink, we continue to be the most clinically advanced company industrializing off-the-shelf and variant natural killer T cells. Based on our observations and experience with these cells, we continue to believe that these are the most important cells for immune reconstitution and disease elimination. We'll talk about a little bit of that today. We're pioneering the science, and as you can see from all our financials, we have some of the most disciplined operations and efficient use of capital in this space. In the first half of this year, we've made meaningful clin...